Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

MPN Research Foundation Announces 2019-2020 Grantees for MPN Challenge Grant program
  • USA - English

The MPN Research Foundation announces grantees awarded as part of the MPN Challenge Grant program, a partnership between MPNRF and The Leukemia and Lymphoma Society.


News provided by

MPN Research Foundation

Sep 25, 2019, 12:00 ET

Share this article

Share toX

Share this article

Share toX

CHICAGO, Sept. 25, 2019 /PRNewswire-PRWeb/ -- The MPN Research Foundation is thrilled to announce the award of seven new projects as part of the MPN Challenge Grant program, a partnership between MPNRF and The Leukemia & Lymphoma Society. The following projects applied and reviewed in a competitive, peer-reviewed process that took place this past July in Chicago. Andrew Schafer, MD, a Richard T. Silver, M.D. Myeloproliferative Neoplasms (MPN) Center at Weil Cornell Professor and the Chair of MPNRF's Scientific Advisory Board commented: "As reflected by the institutions represented, the MPN Challenge grant is now the leading funding source for the most competitive MPN research grant applications worldwide."

The projects will receive $100,000 each for up to 2 years. They are:

            - Matyas Ecsedi, MD, PhD, Fred Hutchinson Cancer Research Center "A JAK2 V617F -
            directed T cell receptor transgenic T cell immunotherapy for the treatment of
            myeloproliferative neoplasms" Partial funding in year one is being provided by the Fred
            Hutchinson's Cancer Research Center's Evergreen Fund

            - Yelena Ginzburg, MD Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai
            "Dysregulated iron metabolism plays a pivotal role in polycythemia vera"

            - Vikas Gupta, MD, Princess Margaret Cancer Center, University Health Network
            "Feasibility of a patient preferences-controlled study of allogenic hematopoietic cell
             transplantation versus best available non-transplant therapies in patients with
             myelofibrosis (ALLO-BAT Study)"

         - Catriona Jamieson, PhD, University of California, San Diego "Detection and Inhibition of
            Malignant RNA Processing Deregulation in Myelofibrosis"

         - Alison Moliterno, MD, Johns Hopkins University School of Medicine "Targeting
            Thrombopoietin Signaling in the MPN"

         - Jyoti Nangalia, MD, PhD, Welcome Sanger Institute "Origins of MPN: Understanding the
            timing of acquisition of driver mutations and dynamics of clonal expansion."

         - Vijay Sankaran, MD, PhD, Boston Children's Hospital "Dissecting Germline Genetic Risk
            for Myeloproliferative Neoplasms"

The timing of these awards and their hoped-for impact is significant for the community of people living with a myeloproliferative neoplasm. Despite the wealth of knowledge on these rare, chronic blood cancers, and the 2 FDA approved therapies, there are still many unmet needs for people with Polycythemia Vera, Essential Thrombocythemia, and Myelofibrosis.

Barbara Van Husen, Chairperson of the MPNRF board of directors, noted that this unmet need was especially meaningful to MPNRF following founder Bob Rosen's death in 2018 from complications of MPN. "We are living out Bob's legacy on behalf of patients everywhere who look to us to fund research that will one day provide what didn't happen for Bob, which is more and better therapy options when they are needed."

This year is the 7th year of the Challenge grant program. It represents a partnership between the MPN Research Foundation and the Leukemia & Lymphoma Society based on a shared mission to support research into blood cancers.

About MPN Research Foundation (MPNRF)
To date, MPNRF has given over $13 million in funding for research into myeloproliferative neoplasms. The mission of MPNRF is to stimulate original research in pursuit of new treatments - and eventually a cure - for the blood cancers Polycythemia Vera, Essential Thrombocythemia, and Myelofibrosis, known collectively as myeloproliferative neoplasms (MPN). MPNRF is proposing their 20th anniversary of funding research, sharing news on the latest discoveries, raising awareness and advocating on behalf of those living with an MPN.
For more about their work visit http://www.mpnrf.org.

I, Lexi Moore, am an authorized distributor of news and have authorization to use the company's name, The MPN Research Foundation, in press releases.

SOURCE MPN Research Foundation

Related Links

http://www.mpnrf.org

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.